Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Decitabine in Accelerated or Blastic Phase CML
NCT00054431Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in chronic myelogenous leukemia (CML), sponsored by National Cancer Institute. Primary endpoints: Complete and partial response at 6 months, Hematologic improvement at 1 year and 1 more. Started Jan 2003; status: completed.
02
Drugs
decitabine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00054431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054431.